Paper · 24256730
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Ostrem JM and 4 others. Nature, 2013. Cited by 2,104 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Papers, record 24256730. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24256730
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Allosteric Site | Major topic |
| Guanosine Diphosphate | Major topic |
| Guanosine Triphosphate | Major topic |
| Mutant Proteins | Major topic |
| Oncogene Protein p21(ras) | Major topic |
| Allosteric Regulation | |
| Apoptosis | |
| Cell Line, Tumor | |
| Crystallography, X-Ray | |
| Cysteine | |
| Drug Discovery | |
| Genes, ras | |
| Humans | |
| Lung Neoplasms | |
| Models, Molecular | |
| Static Electricity | |
| Substrate Specificity | |
| raf Kinases |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Howard Hughes Medical Institute | United States | PubMed | PubMed | ||
| T32 GM064337 | NIGMS NIH HHS | United States | T32GM064337 | PubMed and NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 24,256,732 | Drug discovery: Pocket of opportunity. | https://conductscience.org/library/papers/24256732 | PubMed |
| Comment in | 24,304,874 | Oncogenes: direct hit on mutant RAS. | https://conductscience.org/library/papers/24304874 | PubMed |
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3,145,408 | Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. | Mol Cell Biol | 1988 | https://conductscience.org/library/papers/3145408 | PubMed |
| 2 | 9,043,664 | Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. | Bioorg Med Chem | 1997 | https://conductscience.org/library/papers/9043664 | PubMed |
| 3 | 6,148,751 | Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. | Proc Natl Acad Sci U S A | 1984 | https://conductscience.org/library/papers/6148751 | PubMed |
| 4 | 2,406,906 | Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. | Science | 1990 | https://conductscience.org/library/papers/2406906 | PubMed |
| 5 | 21,500,860 | Simple one-pot synthesis of disulfide fragments for use in disulfide-exchange screening. | ACS Comb Sci | 2011 | https://conductscience.org/library/papers/21500860 | PubMed |
| 6 | 2,199,829 | K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. | N Engl J Med | 1990 | https://conductscience.org/library/papers/2199829 | PubMed |
| 7 | 2,200,519 | Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. | Biochemistry | 1990 | https://conductscience.org/library/papers/2200519 | PubMed |
| 8 | 23,630,290 | In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23630290 | PubMed |
| 9 | 22,566,140 | Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. | Angew Chem Int Ed Engl | 2012 | https://conductscience.org/library/papers/22566140 | PubMed |
| 10 | 2,476,675 | Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. | Nature | 1989 | https://conductscience.org/library/papers/2476675 | PubMed |
1 to 10 of 29
See all 29 referencesCited by1,418
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,104 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,972,081 | A selective TNKS2 inhibitor for tumor-restricted WNT suppression. | Nat Chem Biol | 2026 | https://conductscience.org/library/papers/42972081 | PubMed |
| 42,963,543 | KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42963543 | PubMed |
| 42,958,559 | Targeted protein degradation in cancer: strategies for undruggable targets and progress towards clinical translation. | Biomark Res | 2026 | https://conductscience.org/library/papers/42958559 | PubMed |
| 42,957,732 | Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS. | Nat Commun | 2026 | https://conductscience.org/library/papers/42957732 | PubMed |
| 42,943,275 | Drugging the Undruggable in Oncology: Structural Computation, Machine Learning, and Generative AI for Historically Intractable Targets. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943275 | PubMed |
| 42,936,912 | Uncovering KRAS-mutant allele-specific biology and vulnerabilities in non-small cell lung cancer. | Biochem J | 2026 | https://conductscience.org/library/papers/42936912 | PubMed |
| 42,924,280 | Drugging the "undruggable" p53: a structure-guided strategy against the Y220C mutation. | Med Rev (2021) | 2026 | https://conductscience.org/library/papers/42924280 | PubMed |
| 42,922,582 | Engineered caspases directly rewire mutant Ras to cell death. | bioRxiv | 2026 | https://conductscience.org/library/papers/42922582 | PubMed |
| 42,899,594 | In Pursuit of Enduring Inactivation: A Perspective on the Development and Study of Irreversible-Covalent Inhibitors. | Biochemistry | 2026 | https://conductscience.org/library/papers/42899594 | PubMed |
| 42,892,656 | Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells. | Amino Acids | 2026 | https://conductscience.org/library/papers/42892656 | PubMed |
1 to 10 of 1,418
See all 1,418 cited byGenes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| GSTK1 | 373,156 | PubTator's text mining | https://conductscience.org/library/genes/373156 | NCBI Gene |
| HRAS | 3,265 | PubTator's text mining | https://conductscience.org/library/genes/3265 | NCBI Gene |
| KRAS | 3,845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| NCKAP5 | 344,148 | PubTator's text mining | https://conductscience.org/library/genes/344148 | NCBI Gene |
| RAF1 | 5,894 | PubTator's text mining | https://conductscience.org/library/genes/5894 | NCBI Gene |
| XYLT2 | 64,132 | PubTator's text mining | https://conductscience.org/library/genes/64132 | NCBI Gene |
| ZHX2 | 22,882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24256730
GET https://conductscience.org/api/papers/v1/24256730/references?page=2